Identifying diagnostic criteria for hyperviscosity syndrome in Waldenström Macroglobulinemia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical study focuses on patients with Waldenström Macroglobulinemia (WM) to develop a diagnostic system for hyperviscosity syndrome (HVS). It aims to evaluate both objective symptoms, such as bleeding and fundoscopic findings, and subjective symptoms like fatigue and comorbidities that may affect symptom severity. Patients will undergo assessments including fundoscopic pictures, blood samples, and bone marrow samples to gather comprehensive data. The study seeks to establish clearer diagnostic criteria for HVS, which is often a reason for initiating therapy in WM patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient with WM
* Patients that may require a first-line or subsequent-line therapy
* patients who will require treatment initiation
* patients with serum monoclonal component concentration greater than 15 g/L and who will underwent hyperviscosity assessment, even if hyperviscosity is not found and in the absence of other treatment criteria, no treatment is finally initiated.
* Patients agreeing to give informed consent.

Exclusion Criteria:

* Patients with another chronic B-cell malignancy
* patients with lymphoplasmacytic proliferations
* patients with marginal zone lymphoma.
* patients with WM and histologic transformation
* Absence of informed consent.

Where it's running

• CHU Amiens
  Amiens, France Recruiting

Study contacts

• Study coordinator: Magalie JORIS, MD
• Email: joris.magalie@chu-amiens.fr
• Phone: 03 22 45 54 19

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Pirtobrutinib combined with venetoclax and rituximab for Waldenström's macroglobulinemia

  This treatment tries combining pirtobrutinib, venetoclax, and rituximab in people newly diagnosed with Waldenström's macroglobulinemia (WM)/lymphoplasmacytic lymphoma to see if it controls the disease.

  Recruiting at 9 sites Phase 2 Memorial Sloan Kettering Cancer Center · Boston, Massachusetts and 8 other locations · NCT07231952

• New therapy dose test for people with prior B-cell cancers

  This early-phase study tests different doses of LY4152199 to see if it is safe and effective for people who have already been treated for certain B-cell lymphomas.

  Recruiting at 25 sites Phase 1 Eli Lilly and Company · Duarte, California and 50 other locations · NCT07101328

• Personalized exercise and nutrition program to reduce cancer-related fatigue

  This program will try a personalized exercise and diet plan to reduce fatigue for adults with indolent lymphomas (including CLL/SLL and follicular lymphoma).

  Recruiting UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT06860880

• Zanubrutinib with bendamustine and rituximab for untreated Waldenström macroglobulinemia

  This treatment will try zanubrutinib together with bendamustine and rituximab to see if it produces deep responses in people with untreated Waldenström macroglobulinemia.

  Recruiting at 5 sites Phase 2 Massachusetts General Hospital · Denver, Colorado and 4 other locations · NCT06561347

• Treatment for relapsed or refractory B-cell lymphoma using SynKIR-310

  This study is testing a new treatment called SynKIR-310 to see if it can help adults with relapsed or refractory B-cell lymphoma feel better.

  Recruiting at 5 sites Phase 1 Verismo Therapeutics · Denver, Colorado and 4 other locations · NCT06544265

• Using epcoritamab to treat previously treated Waldenstrom Macroglobulinemia

  This study is testing if a new treatment called epcoritamab can help people with Waldenstrom Macroglobulinemia who have already received other treatments.

  Recruiting at 3 sites Phase 2 Beth Israel Deaconess Medical Center · Boston, Massachusetts and 2 other locations · NCT06510491

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.